Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
GTBP
GTBP
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
GTBP News
GT Biopharma: Three Drugs Enter Human Trials
1d ago
PRnewswire
GT Biopharma Advances Three Drug Candidates in Clinical Trials
1d ago
Newsfilter
GT Biopharma Advances NK Cell Immunotherapy with TriKE Candidates
May 19 2026
Newsfilter
GT Biopharma Initiates GTB-5550 Clinical Trial for B7-H3 Targeting
May 18 2026
PRnewswire
GT Biopharma Doses First Patient in GTB-5550 Clinical Trial
May 18 2026
Newsfilter
GT Biopharma Reports Q2 2026 Financial Results
May 15 2026
seekingalpha
GT Biopharma Initiates Phase 1 Trial of GTB-5550 for Solid Tumors
May 14 2026
Newsfilter
GT Biopharma Launches Clinical Trial for B7-H3 Targeted Therapy
May 14 2026
Newsfilter
GTB-5550 Enters Clinical Trials for Solid Tumors
May 14 2026
Newsfilter
GT Biopharma Reports $28.4 Million Net Loss for FY2025
Mar 02 2026
seekingalpha
GT Biopharma Initiates Phase 1 Trial for GTB-5550
Feb 03 2026
Newsfilter
Ventripoint Partners with Nisg̱a'a to Enhance Cardiac Diagnostics with AI Technology
Jan 16 2026
Globenewswire
Ventripoint Partners with Nisg̱a'a Valley to Enhance Cardiac Diagnostics
Jan 16 2026
Newsfilter
GT Biopharma Submits IND for GTB-5550 Targeting $362 Billion Solid Tumor Market
Jan 16 2026
PRnewswire
GT Biopharma Submits IND for GTB-5550, Aiming for 2026 Clinical Trials
Jan 15 2026
NASDAQ.COM
GT Biopharma (GTBP) Submits IND Application for GTB-5550, Plans Phase 1 Trial in 2026
Jan 15 2026
NASDAQ.COM
Show More News
